Glioblastoma Multiforme

Edland, Robert W.; Javid, Manucher J.; Ansfield, Fred J.

doi:10.2214/ajr.111.2.337

Cited by 36 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of cytotoxic agents, either before or together with cerebral irradiation, has theoretical advantages which also need to be explored. In a recent randomized trial, however, a combination of irradiation and 5-fluorouracil had no advantage over irradiation alone for patients with glioblastoma (Edland, Javid and Ansfield, 1971 …”

Section: Resultsmentioning

confidence: 96%

Glioblastoma Multiforme: A Controlled Trial to Assess the Value of Specific Active Immunotherapy in Patients Treated by Radical Surgery and Radiotherapy

Bloom¹,

Peckham²,

Richardson³

et al. 1973

Br J Cancer

109

View full text Add to dashboard Cite

Summary.-The results are reported of a randomized prospective clinical trial carried out to assess the value of specific active immunotherapy using irradiated autologous tumour cells in patients with glioblastoma multiforme treated by radical surgery and post-operative irradiation. The results in 62 patients show no statistically significant difference in survival between the group receiving adjuvant autologous tumour cells and those treated with surgery and radiotherapy alone. All 27 patients receiving tumour cells were dead at 30 months, whereas 7 of the 35 controls were alive at this time. The results were considered sufficiently discouraging to abandon the trial at this stage on the grounds that there was sufficient evidence in this study that the administration of irradiated autologous cells was of no benefit to patients with high grade astrocytomata.

show abstract

Section: Resultsmentioning

confidence: 96%

Glioblastoma Multiforme: A Controlled Trial to Assess the Value of Specific Active Immunotherapy in Patients Treated by Radical Surgery and Radiotherapy

Bloom¹,

Peckham²,

Richardson³

et al. 1973

Br J Cancer

109

View full text Add to dashboard Cite

show abstract

“…With the advent of personalized medicine, the therapeutic strategies also need to be upgraded to individual centric rather than population centric approaches. Considering the wide variability in pro-carcinogenic factors amongst patients, personalized approaches could probably result in better patient outcome (Buckley, 1929;Sachs, 1954;Jelsma and Bucy, 1967;Edland et al, 1971;Ramsey and Brand, 1973;Rosenblum et al, 1973;Tani et al, 1973;Marton et al, 1974;Yung et al, 1976;Heiss, 1978;Morantz et al, 1979;Neuwelt et al, 1980; Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.…”

Section: Discussionmentioning

confidence: 99%

Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches

Tripathy,

Panda,

Biswal

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Glioblastoma (GB) is an intrusive and recurrent primary brain tumor with low survivability. The heterogeneity of the tumor microenvironment plays a crucial role in the stemness and proliferation of GB. The tumor microenvironment induces tumor heterogeneity of cancer cells by facilitating clonal evolution and promoting multidrug resistance, leading to cancer cell progression and metastasis. It also plays an important role in angiogenesis to nourish the hypoxic tumor environment. There is a strong interaction of neoplastic cells with their surrounding microenvironment that comprise several immune and non-immune cellular components. The tumor microenvironment is a complex network of immune components like microglia, macrophages, T cells, B cells, natural killer (NK) cells, dendritic cells and myeloid-derived suppressor cells, and non-immune components such as extracellular matrix, endothelial cells, astrocytes and neurons. The prognosis of GB is thus challenging, making it a difficult target for therapeutic interventions. The current therapeutic approaches target these regulators of tumor micro-environment through both generalized and personalized approaches. The review provides a summary of important milestones in GB research, factors regulating tumor microenvironment and promoting angiogenesis and potential therapeutic agents widely used for the treatment of GB patients.

show abstract

“…The routine use of RT in brain tumors began in the 1940s with kilovoltage X-rays (13,14). In the 1960s, 45-60 Gy RT was applied to the entire brain with megavoltage X-rays or Co-60 teletherapy devices (15,16). We found that all the OARs and whole brain tissue received a median [standard deviation (SD)] dose of 45 (3) Gy, except for lenses, when 45 Gy WBRT was delivered after 2D planning through Co-60 or linear accelerators.…”

Section: Discussionmentioning

confidence: 99%

Changing Trends in Radiotherapy for Glioblastoma Multiforme and Effects on Normal Tissue Doses

İbiş¹,

Koksal²,

Akbas³

et al. 2019

Istanbul Med J

View full text Add to dashboard Cite

Amaç: Çalışmanın amacı glioblastoma multiforme (GBM) radyoterapisindeki (RT) geçmişten günümüze değişen eğilimlerin ortaya konulması ve risk altındaki organ dozlarındaki değişimin gösterilmesidir. Yöntemler: GBM tanısı ile postopereatif temozolamid ve RT ile tedavi edilen 10 hastanın simülasyon bilgisayarlı tomografi görüntüleri retrospektif olarak incelenerek pre-ve postoperatif manyetik rezonans görüntüleri (MRG) ile rjiid füzyon yapıldı ve 9 ayrı volüm oluşturuldu. Volümler total kranyum ışınlamadan postoperatif iki fazlı ışınlamaya değişkenlik gösterirken, RT uygulaması 2-boyutlu (2B) Co-60 tedavisinden 3-boyutlu (3B) volumetrik ark tedaviye (VMAT) değişiyordu. Risk altındaki organlar (organs at risk-OAR) konturlandı. Beyin-hedef hacmi planlama (PTV) D mean , beyin sapı D max , göz D max ipsilateral/ kontralateral, kiazma D max , koklea D mean ipsilateal/kontralateral, lakrimal gland D max ipsilateral/konrtalateral, lens D max ipsilateral/ kontralateral, pituiter gland D max dozları kaydedildi. 7, 8, 9. planlar (preop MRG'den oluşturulan volümün 3B-konformal RT-3B-KRT planı ile postop MRG'den oluşturulan 3B-KRT ve VMAT planları) karşılaştırıldı. Paired sample t-testi ile istatistiksel analiz yapıldı. Bulgular: Total kranyum RT uygulandığı dönemlerde normal beyin dokusunun hepsi 45-60 Gy alırken VMAT ile beyin-PTV D mean medyan 35 Gy'e düşmüştür. Aynı zamanda göz ve lensler dışında risk altındaki organlar verilen tüm dozu alarak 60 Gy uygulanan gruplarda doz sınırlamaları aşılmıştır. Hem PTV-Radyasyon Terapisi Onkoloji Grubu (RTOG) preop hem de PTV-RTOGpostop 3D-CRT planına göre beyin-PTVinitial volüm Dmean ve beyin-PTVboost Dmean dozları dahil olmak üzere tüm OAR dozlarında iki plan arasında istatistiksel anlamlı fark yoktu. VMAT planı ile hem PTV-RTOGpreop hem de PTV RTOGpostop volümlerine göre yapılan 3D-CRT planlarından istatistiksel anlamlı daha düşük OAR dozları elde edildi. Sonuç: Tarihsel süreçte ışınlanan volüm ve normal doku dozlarında belirgin azalma olmuştur. RTOG'nin postoperatif volüm tanımına göre konformal ve VMAT planları karşılaştırıldığında VMAT planlamada daha düşük normal doku dozları elde edilmektedir. Anahtar Kelimeler: 3D konformal radyoterapi, yoğunluk ayarlı radyoterapi, glioblastoma multiforme, volümetrik ark tedavisi Introduction: The aim of the study is to reveal the changing trends in radiotherapy (RT) for glioblastoma multiforme (GBM) from past to present and to show the changes in organs at risk (OARs) doses. Methods: We re-planned 10 GBM patients who were previously irradiated. Rigid fusion was performed through pre-and postoperative magnetic resonance imaging (MRI) and simulation computed tomography, and 9 separate volumes were created. While volumes varied from whole brain RT (WBRT) to postoperative two-phase irradiation, RT application ranged from 2-dimensional Co-60 treatment to 3-dimensional volumetric modulated arc therapy (VMAT). OARs were contoured, and doses were noted. A 3 dimensional-conformal RT (3D-CRT) plan of the volume created by preoperative MRI was compared to...

show abstract

Glioblastoma Multiforme

Cited by 36 publications

References 0 publications

Glioblastoma Multiforme: A Controlled Trial to Assess the Value of Specific Active Immunotherapy in Patients Treated by Radical Surgery and Radiotherapy

Glioblastoma Multiforme: A Controlled Trial to Assess the Value of Specific Active Immunotherapy in Patients Treated by Radical Surgery and Radiotherapy

Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches

Changing Trends in Radiotherapy for Glioblastoma Multiforme and Effects on Normal Tissue Doses

Contact Info

Product

Resources

About